Comprehensive pharmacology and clinical efficacy of aromatase inhibitors

Drugs

Volumn 58, Issue 2, 1999, Pages 233-255

  Njar, Vincent C O ^a,b   Brodie, Angela M H ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; MEGESTROL; PYRIDOGLUTETHIMIDE; TAMOXIFEN; TESTOLACTONE; VOROZOLE;

ABSCESS; ACNE; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CLINICAL TRIAL; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INHIBITION; ESTROGEN SYNTHESIS; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HOARSENESS; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERTRICHOSIS; INTRAMUSCULAR DRUG ADMINISTRATION; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; RASH; REVIEW; SOMNOLENCE;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; MALE;

EID: 0032790550     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958020-00003     Document Type: Review

References (193)

1. 1. Thompson EA Jr, Siiteri PK. The involvement of human placental microsomal cytochrome P-450 in aromatization. J Biol Chem 1974; 249: 5373-8
2. 2. Thompson EA Jr, Siiteri PK. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J Biol Chem 1974; 249 (17): 5364-73
3. 3. Skinner SJM, Akhtar M. The stereospecific removal of a C-19 hydrogen atom in oestrogen biosynthesis. Biochem J 1969; 144: 75-81
4. 4. Wright JN, Akhtar M. Studies on estrogen biosynthesis using radioactive and stable isotopes. Steroids 1990; 55: 142-51
5. 5. Cole PA, Robinson CH. Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem 1990; 33: 2933-44
6. 6. Akhtar M, Njar VCO, Wright JN. Mechanistic studies on aromatase and related C-C bond cleaving P-450 enzymes. J Steroid Biochem Mol Biol 1993; 44: 375-87
7. 7. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1996; II: 104-7
8. 8. Bayliss WM, Starling EH. The mechanism of pancreatic secretion. J Physiol 1902; 28: 325-53
9. 9. McGuire WL. An update on estrogen and progesterone receptors in prognosis for primary and advanced breast cancer. In: lacobelli S, King RJB, Linder HR, et al., editors. Hormones and cancer. New York: Raven Press, 1980; Vol. 14: 337-44
10. 10. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1-15
11. 11. Schwarzel WC, Kruggel W, Brodie HJ. Studies on the mechanism of estrogen biosynthesis. VII. The development of inhibitors of the enzyme system in human placenta. Endocrinology 1973; 92: 866-80
12. 12. Brodie AMH, Schwarzel WC, Shaikh AA, et al. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 1977; 100: 1684-94
13. 13. Coombes RC, Goss P, Dowsett M, et al. 4-Hydroxyandro-stenedione treatment of postmenopausal patients with advanced breast cancer. Lancet 1984; II: 1237-9
14. 14. Goss PE, Coombes RL, Powless TJ, et al. Treatment of advanced postmenopausal breast cancer with aromatase inhibitor, 4-hydroxyandrostenedione - Phase 2 report. Cancer Res 1986; 46: 4823-6
15. 15. Roselli CE, Horton LE, Resko JA. Distribution and regulation of aromatase activity in the rat hypothalamus and limbic systems. Endocrinology 1985; 117: 2471-7
16. 16. Longcope C, Pratt JH, Schneider SH, et al. Aromatization of androgens by muscle and adipose tissue in vivo. J Clin Endocrinol Metab 1978; 46: 146-52
17. 17. Brodie AMH, Inkster SE. Aromatase in the human testis. J Steroid Biochem Mol Biol 1993; 44: 4-6
18. 18. Payne AH, Perkins LM, Georgiou M, et al. Intratesticular site of aromatase activity and possible function of testicular estradiol. Steroids 1987; 50: 435-48
19. 19. Baird DT, Horton K, Longcope C, et al. Steroid dynamics under steady-state conditions. Recent Prog Horm Res 1969; 25: 611-34
20. 20. Inkster SE, Brodie AMH. Immunocytochemical studies of aromatase in early and full term human placental tissues: comparison with biochemical assays. Biol Reprod 1989; 41: 889-98
21. 21. Naftolin F, Ryan KJ, Davis IJ, et al. The formation of estrogen by central neuroendocrine tissues. Recent Prog Horm Res 1975; 31: 295-319
22. 22. Inkster SE, Brodie AMH. Expression of aromatase cytochrome P-450 in premenopausal and postmenopausal human ovaries: an immunocytochemical study. J Clin Endocrinol Metab 1991; 73: 717-26
23. 23. Hemsell DL, Grodin J, Breuner PF, et al. Plasma precursors of estrogen. II. Correlalion of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 1974; 38: 476-9
24. 24. Thorsen T, Tangen M, Stoa KF. Concentrations or endogenous estradiol as related to estradiol receptor sites in breast tumor cytosol. Eur J Cancer Clin Oncol 1982; 18: 333-7
25. 25. van Landeghem AAJ, Portman J, Nabauurs M, Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 1985; 45: 2900-6
26. 26. Perel E, Blackstein ME, Killinger DW. Aromatase in human breast carcinoma. Cancer Res Suppl.: 1982; 42: 3369s-72s
27. 27. James VHT, McNeill JM, Lai L, et al. Aromatase activity in normal breast and breast tumor tissue: in vivo and in vitro studies. Steroids 1987; 50: 269-79
28. 28. Killinger DW, Perel E, Daniilescu D, et al. Aromatase activity in the breast and other peripheral tissues and its therapeutic regulation. Steroids 1987; 50: 523-35
29. 29. Miller WR, Hawkins RA, Forrest APM. Significance of aromatase activity in human breast cancer. Cancer Res Suppl.: 1982; 42: 3365s-8s
30. 30. Peice T, Aitken J, Head J, et al. Determination of aromatase cytochrome P-450 messenger ribonucleic acid in human breast tissue by competitive polymerase chain reaction amplification. J Clin Endocrinol Metab 1992; 174: 1247-52
31. 31. Koos RD, Banks PK, Inkster SE, et al. Detection of aromatase and keratinocyte growth factor expression in breast tumors using reverse transcription-polymerase chain reaction. J Steroid Biochem Mol Biol 1993; 45: 217-25
32. 32. Lu Q, Nakmura J, Savinov A, et al. Expression of aromatase protein and mRNA in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancer. Endocrinology 1996; 137: 3061-8
33. 33. Bezwoda WR, Mansoor N, Dansey R. Correlation of breast tumor aromatase activity and response to aromatase inhibitor with aminoglutethimide. Oncology 1987; 44: 345-9
34. 34. Miller WR, Anderson TJ, Jack WLJ. Relationship between tumor aromatase activity, tumor characteristics and response to therapy. J Steroid Biochem Mol Biol 1990; 44: 1055-9
35. 35. Bradlow HL. A reassessment of the role of breast tumor aromatization. Cancer Res Suppl.: 1982; 42: 3382s-6s
36. 36. Sasano H, Nagura H, Harada N, et al. Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Human Pathol 1994; 25: 530-5
37. 37. Santen RJ, Martel J, Hoahland F, et al. Stromal spindle cells contain aromatase in human breast tumors. J Clin Endocrin Metab 1994; 79: 627-32
38. 38. Esteban JM, Warsi Z, Haniu M, et al. Detection of intratumoral aromatase in breast carcinomas. Am J Pathol 1992; 140: 337-43
39. 39. Chen S, Besman MJ, Sparkes RS, et al. Human aromatase: cDNA cloning. Southern blot analysis, and assignment of the gene to chromosome 15. DNA Mol Biol 1988; 7: 27-38
40. 40. Simpson ER, Mehendroo MS, Means GD, et al. Tissue-specific promoters regulate cytochrome P-450 expression. J Steroid Biochem Mol Biol 1993; 44: 321-30
41. 41. Hseuh AJW, Adashi EY, Jones PBC, et al. Hormonal regulation of the differentiation of cultured ovarian granulosa cells. Endocrinol Rev 1984; 5: 76-127
42. 42. Simpson ER, Ackerman GE, Smith ME, et al. Estrogen formation in stromal cells of adipose tissue of women: induction of glucocorticosteroids. Proc Natl Acad Sci USA 1981; 78: 5690-4
43. 43. Mendelson CR, Cleland WH, Smith ME, et al. Regulation of aromatase activity of stromal cells derived from human adipose tissue. Endocrinology 1982; 111: 1077-85
44. 44. Corbin CJ, Graham-Lorence S, McPhaul M, et al. Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in non-steroidogenic cells. Proc Natl Acad Sci USA 1988; 85: 8948-53
45. 45. Nebert DW, Nelson DR, Coon MJ, et al. The P-450 superfamily: update on new sequences, gene mapping and recommended nomenclature. DNA Mol Biol 1991; 10: 1-14
46. 46. Santen RJ, Santner S, Lipton A, editors. Aromatase: new perspectives for breast cancer. Cancer Res Suppl.: 1982; 42: 3267s-468s
47. 47. Santen RJ, editor. Aromatase: future perspectives. Steroids 1987; 50: 1-665
48. 48. Goss PE, Gwyn KMEH. Current perspectives on aromatase inhibitors in breast cancer. J Clin Oncol 1994; 12: 2460-70
49. 49. Brodie A, Brodie HR, Callard G, et al., editors. Recent advances in steroid biochemistry and molecular biology. Proceedings of the Third International Aromatase Conference basic and clinical aspects of aromatase. J Steroid Biochem Mol Biol 1993; 44: 321-693
50. 50. Covey DF. Aromatase inhibitors: specific inhibition of oestrogen biosynthesis. In: Berg D, Plempel M, editors. Steroid biosynthesis inhibitors. Chichester: Allis Norwood Ltd, 1988: 534-71
51. 51. Brueggemeier RW. Biochemical and molecular aspects of aromatase. J Enzym Inhib 1990; 4: 101-11
52. 52. Brodie AMH, Njar VCO. Aromatase inhibitors and breast cancer. Semin Oncol 1996; 23 Suppl.: 10-20
53. 53. Ryan KJ. Biological aromatization of steroids. J Biol Chem 1959; 234: 268-72
54. 54. Brodie AMH, Schwarzel WC, Brodie HJ. Studies on the mechanism of estrogen biosynthesis in the rat ovary - 1. J Steroid Biochem 1976; 7: 787-93
55. 55. Brodie HJ, Kripalani KJ, Possanza G. Studies on the mechanism of estrogen biosynthesis. IV: The stereochemistry of hydrogen elimination of C-2 during aromatization. J Am Chem Soc 1969; 91: 1241-5
56. 56. Frouckowiak MD, Osawa Y. Atomatization of 2-beta labeled testosterone occurs under two different stereomechanisms, 1-beta-elimination being a conserved feature. [abstract 430]. The 70th Annual Meeting of the Endocrine Society, 1988 Jun 8-11; New Orleans (LA)
57. 4H]androgens into estrogens by human placental aromatase. Biochem J 1990; 268: 553-61
58. 58. Brodie AM, Garrett WM, Hendrickson JR, et al. Inactivation of aromatase activity in placenta and ovarian microsomes by 4-hydroxyandrostene-3,17-dione and 4-acetoxyandrostene-3,17-dione. Steroids 1981; 38: 693-702
59. 59. Brodie AMH, Son C, King DA, et al. Lack of aromatase in human prostatic tissue: effects of 4-OHA and other inhibitors on androgen metabolism. Cancer Res 1989; 49: 6551-5
60. 60. Johnston JO, Wright CL, Metcalf BW. Time-dependent inhibition of aromatase in trophoblastic tumor cells in tissue culture. J Steroid Biochem 1984; 20: 1221-6
61. 61. Kitawaki J, Kim T, Kanno H, et al. Growth suppression of MCF-7 human breast cancer cells by aromatase inhibitors: a new system for aromatase inhibitor screening. J Steroid Biochem Mol Biol 1993; 44: 667-70
62. 62. Macaulay VM, Nicholls JE, Gledhill J, et al. Biological effects of stable overexpression of aromatase in human hormone-depedent breast cancer cells. Br J Cancer 1994; 69: 77-83
63. 63. Zhou D, Pompon D, Chen S. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 1990; 50: 6949-54
64. 64. Yue W, Brodie A. Mechanism of the actions of aromatase inhibitors 4-OHA, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell cultures. J Steroid Biochem Mol Biol 1997; 63: 317-28
65. 65. Long B, Tilghman S, Yue W, et al. The steroidal antiestrogen 1CI 182,780 is an inhibitor of cellular aromatase activity. J Steroid Biochem Mol Biol 1998; 67 (4): 293-304
66. 66. Brodie AMH, Wu J-T, Marsh DA, et al. Aromatase inhibitors III. Studies on the antifertility effect of 4-acetoxy-4-androstene-3,17-dione. Biol Reprod 1978; 18: 365-70
67. 67. Geyer RP, Bryant JE, Bliesch VR, et al. Effect of dose and hormones on tumor production in rats given 9,10-dimethyl-1,2-benzanthracene intravenously. Cancer Res 1953; 13: 503-6
68. 68. Brodie AMH, Wing LY, Goss P, et al. Aromatase inhibitors and their potential clinical significance. J Steroid Biochem 1986; 25: 859-65
69. 69. Wing LY, Garrett WM, Brodie AMH. The effect of aromatase inhibitors, aminoglutethimide and 4-hydroxyandrostenedione in cyclic rats with DMBA-induccd mammary tumors. Cancer Res 1985; 45: 2425-8
70. 70. Yue W, Brodie A. A nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 1994; 54: 5092-5
71. 71. Yue W, Wang J, Savinov A, et al. The effect of aromatase inhibitors on growth of mammary tumors in nude mouse model. Cancer Res 1995; 55: 3073-7
72. 72. Lu Q, Yue W, Wang J, et al. The effect of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res Treat 1998; 50 (1): 63-71
73. 73. Brodie AMH, Longcope C. Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy-and 4-acetoxy-androstene-3,17-dione. C. Endocrinology 1980; 106: 19-21
74. 74. Longcope C, Femino A, Johnston JO. Inhibition of peripheral aromatization in baboons by an enzyme-activated aromatase inhibitor (MDL 18,962). Endocrinology 1988; 122: 2007-11
75. 75. Santen RJ, Santner S, Davis B, et al. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 1978; 47: 1257-65
76. 76. Lonning PE, Ekse D. A sensitive assay for measurement of plasma oestrogen sulphate in patients on treatment with aromatase inhibitors. J Steroid Biochem Mol Biol 1995; 55: 409-12
77. 77. Dowsett M, Cunningham DC, Stein RC, et al. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 1989; 49: 1306-12
78. 78. Lonning PE, Helle SI, Johannessen DC, et al. Relations between sex hormones binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-I in postmenopausal breast cancer patients. Clin Endocrinol 1995; 42: 23-30
79. 79. Dukes M, Edwards PN, Large M, et al. The preclinical pharmacology of Arimidex (anastrozole: ZD 1033) a potent, selective aromatase inhibitor. J Steroid Biochem Mol Biol 1996; 58: 439-45
80. 80. Jacobs S, Lonning PE, Haynes B, et al. Measurement of aromatization by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. J Enzym Inhib 1991; 4: 315-25
81. 81. Dowsett M, Jones A, Johnston SRD, et al. In vivo measurements of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995; 1: 1511-5
82. 82. Lonning PE, Geisler J, Johannessen DC, et al. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. J Steroid Biochem Mol Biol 1997; 61: 255-60
83. 83. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatization and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996; 74: 1286-91
84. 84. Lonning PE, Paridaens R, Thurlimann B, et al. Exemestane experience in breast cancer treatment. J Steroid Biochem Mol Biol 1997; 61: 151-5
85. 85. Dowsett M, Lonning PE. Anastrozole a new generation in aromatase inhibition: clinical pharmacology. Oncology 1997; 54: 11-4
86. 86. Dowsett LM, Harris AL, Stuart-Harris R, et al. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients. Br J Cancer 1985; 52: 525-9
87. 87. Demers LM, Lipton A, Harvey HA, et al. The effects of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced breast cancer. J Steroid Biochem Mol Biol 1993; 44: 687-91
88. 88. Reed MJ, Owen AM, Lai LC, et al. In situ oestrogen synthesis in normal breast and breast tumour tissue: effects of treatment with 4-hydroxyandrostenedione. Int J Cancer 1989; 44: 233-7
89. 89. Hayward JL, Carbone PP, Heuson J-C, et al. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977; 13: 89-94
90. 90. European Organisation for Research and Treatment of Cancer. Cancer-related pain and analgesic score: manual for clinical research in breast cancer. EORTC Breast Cancer Cooperative Group, 1991
91. 91. Sjoerdsma A. Suicide inhibitors as potential drugs. Clin Pharmacol Ther 1981; 30: 3-22
92. 92. Tochigi M, Yarhorough C, Osawa Y, et al. Effects of human placental aromatase inactivators on rat ovarian aromatase in vivo [abstract]. 7th International Congress of Endocrinology; 1984; Quebec, Canada, 1478
93. 93. Osawa Y, Osawa Y, Coon MJ. Stereochemistry of the functional group determines the mechanism of aromatase inhibition by 6-bromoandrostenedione. Endocrinology 1987; 121: 1010-6
94. 94. Segaloff A, Weeth JB, Rongone EL, et al. Hormonal therapy in cancer of the breast. Cancer 1960; 13: 1017-20
95. 1-testolactone. J Clin Endocrinol Metab 1979; 49: 672-6
96. 96. Cash R, Brough AJ, Cohen MNP, et al. Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trials. J Clin Endocrinol Metab 1967; 27: 1239-48
97. 97. Samojlik E, Santen RJ, Wells SA. Adrenal suppression with aminoglutethimide II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels. J Clin Endocrinol Metab 1977; 45: 480-7
98. 98. Harris AL, Powles TJ, Smith IE. Aminoglutethimide in the treatment of advanced postmenopausal breast cancer. Cancer Res 1982; 42 Suppl: 3405s-8s
99. 99. Badder EM, Lerman S, Santen RT. Aminoglutethimide stimulates extra-adrenal delta-4 androstenedione production. J Surg Res 1983; 34: 380-7
100. 100. Lonning PE, Kvinnsland S, Thoren T, et al. Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients: preliminary findings. Clin Pharmacokinet 1987; 13: 393-406
101. 101. Lonning PE, Kvinnsland S, Bakkel OM. Effects of aminoglutethimide on antipyrine, theophylline and digitoxin disposition in breast cancer. Clin Pharmacol Ther 1987; 36: 796-802
102. 102. Covey DF, Hood WF. Aromatase enzyme catalysis is involved in the potent inhibition of estrogen biosynthesis caused by 4-acetoxy and 4-hydroxy-4-androstene-3,17-dione. Mol Pharmacol 1982; 21: 173-80
103. 103. Brodie AMH, Wing L-Y. In vitro and in vivo studies with aromatase inhibitor 4-hydroxyandrostendione. Steroids 1987; 50: 89-103
104. 104. Dowsett M, Goss PE, Powles TJ, et al. Use of aromatase inhibitor 4-hydroxyandrostenedione in post-menopausal breast cancer: optimization of therapeutic dose and route. Cancer Res 1987; 147: 195-6
105. 105. Dowsett M, Coombes RC. The development of the new aromatase inhibitor 4-OHA: endocrine and clinical aspects. Proceedings of the Symposium Aromatase inhibition - past, present and future. 15th International Congress; 1990; Hamburg, 9-10
106. 106. Possinger K, Jonat W, Hoffken K. Formestane in the treatment of advanced postmenopausal women with advanced breast cancer. Ann Oncol 1994; 5: S7-10
107. 107. Bajetta E, Zilemba N, Norersco C, et al. Formestane: effective therapy in postmenopausal women with advanced breast cancer. In: Nagel G, Possinger K, editors. Selective aromatase inhibitors: improved quality of life for metastatic breast cancer patients. Wehr/Barden: Ciba-Geigy Verlag, 1996
108. 108. Cunningham D, Powles TJ, Dowsett M, et al. Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer. Cancer Chemother Pharmacol 1987; 20: 253-5
109. 109. Dowsett M, Coombes RC. Second generation aromatase inhibitor 4-OHA. Breast Cancer Res Treat 1994; 30: 81-7
110. 110. Coombes RC, Hughes SWM, Dowsett M. 4-OHA: a new treatment for breast cancer. Eur J Cancer 1992; 28A: 1941-5
111. 111. Dowsett M, Johnston SRD, Haynes BP, et al. Impaired intra-tumoral uptake of tamoxifen as a mechanism for resistance in human breast cancer [abstract 1463]. 84th Annual Meeting of the American Association For Cancer Research; 1993 May 19-22; Orlando (FL)
112. 112. Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 1988; 48: 5183-7
113. 113. Perez Carrion R, Alberola Candel V, Calabresi F, et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 1994; 5 Suppl. 7: 519-24
114. 114. Di Salle E, Giudici D, Ornati G, et al. Endocrine properties of 6-methyleneandrosta-1,4-diene-3,17-dione (FCE 24304), a new irreversible aromatase inhibitor [abstract D-015]. J Steroid Biochem 1987; 28 Suppl.: 146s
115. 115. Giudici D, Ornati G, Briatico G, et al. 6-Methyleneandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. J Steroid Biochem 1988; 30: 391-4
116. 116. Di Salle E, Giudici D, Ornati G, et al. 4-Aminoandrostenedione derivatives: a novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione. J Steroid Biochem Mol Biol 1990; 37: 369-74
117. 117. Zaccheo T, Giudici D, Lambardi P, et al. A new irreversible aromatase inhibitor, 6-methyleneandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effect in rats with DMBA-induced mammary tumors. Cancer Chemother Pharmacol 1989; 23: 47-50
118. 118. Zaccheo T, Di Salle E. Effect of the irreversible aromatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone. Cancer Chemother Pharmacol 1985; 25: 95-8
119. 119. Evans TRT, Di Salle E, Ornati G, et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor in postmenopausal women. Cancer Res 1992; 52: 5933-9
120. 120. Zilembo N, Noberasco C, Bejetta E, et al. Endocrinology and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br J Cancer 1995; 72: 1007-12
121. 121. Johannessen DC, Engan T, Di Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155071) a novel steroidal aromatase inhibitor in postmenopausal breast cancer patients; phase I study. Clin Cancer Res 1997; 3: 1101-8
122. 122. Murray R, Pitt P. Aromatase inhibition with 4-OH-androstenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast Cancer. Breast Cancer Res Treat 1995; 35: 249-53
123. 123. Geisler J, Johannessen DC, Anker G, et al. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients: clinical and endocrine effects. Eur J Cancer 1996; 32: 789-92
124. 124. Foster AB, Jarman M, Leung C-S, et al. Analogues of aminoglutethimide: selective inhibitors of aromatase. J Med Chem 1985; 28: 200-4
125. 125. Leung C-S, Rowlands MG, Jarman M, et al. Analogues of 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione as selective inhibitors of aromatase: derivatives with variable 1-alkyl and 3-alkyl substituents. J Med Chem 1987; 30: 1550-4
126. 126. Santen RJ, Manni A, Harvey H, et al. Endocrine treatment of breast cancer in women. Endocrine Rev 1990; 11: 221-65
127. 127. Seaga A, Goss PE, Griggs LJ, et al. Pyridoglutethimide [3-ethyl-3-(4-pyridyl)piperidine-2,6-dione], an analogue of aminoglutethimide: metabolism and pharmacokinetics. Biochem Pharmacol 1986; 35: 2911-6
128. 128. Haynes BP, Jarman M, Dowsett M, et al. Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer. Cancer Chemother Pharmacol 1991; 27: 367-72
129. 129. Dowsett M, MacNeill F, Mehta A, et al. Endocrine pharmacokinetics and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients. Br J Cancer 1991; 64: 887-94
130. 130. Fox KR, Glick JH, Macdonald JS, et al. Randomized phase II trial of rogletimide in advanced breast cancer: a preliminary report. Breast Cancer Res Treat 1993; 27: 152
131. 131. Schulz J, Fox K, Conner G, et al. A phase II study of rogletimide (RoG) in females with advanced/metastic breast cancer (A/M BrCa) [abstract no. 73]. Proc Am Soc Clin Oncol 1995; 14: 93
132. 132. Harnett AN, Canney P, Coombes RC, et al. A randomised phase II trial of rogletimide in heavily pretreated breast cancer patients [abstract no. 338]. Proc Am Soc Clin Oncol 1995; 14: 176
133. 133. Steele RE, Mellor LB, Sawyer WK, et al. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with nonsteroidal aromatase inhibitor CGS 16949A. Steroids 1987; 50: 147-61
134. 134. Hausler A, Monnet G, Borer C, et al. Evidence that corticosterone is not an obligatory intermediate in aldosterone biosynthesis in the rat adrenal. J Steroid Biochem 1989; 34: 567-70
135. 135. Lamberts SWJ, Bruining HA, Marzouk H, et al. The new aromatase inhibitor CGS 16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro. J Clin Endocrinol Metab 1989; 69: 896-901
136. 136. Schieweck K, Bhatnagar AS, Matter A. CGS 16949A, a new non-steroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo. Cancer Res 1988; 48: 834-8
137. 137. Santen RJ, Demers LM, Adlercreutz H, et al. Inhibition of aromatase with CGS 16949A in postmenopausal women. J Clin Endocrinol Metab 1989; 68: 99-106
138. 138. Lipton A, Harvey HA, Demers LM, et al. A phase I trial of CGS 16949A - a new aromatase inhibitor. Cancer 1990; 65: 1279-85
139. 139. Beratta KR, Hoeffken K, Kvinnsland S, et al. CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer - a phase I study. Ann Oncol 1990; 1: 421-6
140. 140. Raats JI, Falkson G, Folkson HC. A study of fadrozole, a new aromatase inhibitor in postmenopausal women with advanced metastatic breast cancer. J Clin Oncol 1992; 10: 111-6
141. 141. Hoeffken K, Chacon R, Dombernowshk P, et al. Fadrozole hydrochloride (CGS 16949A), a double-blind dose finding study in postmenopausal women with advanced breast cancer. Ann Oncol 1992; 3 Suppl. 5: 76
142. 142. Dowsett M, Stein RC, Mehta A, et al. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol 1990; 32: 623-34
143. 143. Stein RC, Dowsett M, Davenport J, et al. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A. Cancer Res 1990; 50: 1381-4
144. 144. Dowsett M, Smither J, Moore PF, et al. Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. Eur J Cancer 1994; 30: 1453-8
145. 145. Bonnefoi HR, Smith IE, Dowsett M, et al. Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer. Br J Cancer 1996; 73: 539-42
146. 140. Miller AA, Lipton A, Henderson IC, et al. Fadrozole hydrochloride in postmenopausal patients with metastatic breast cancer. Cancer 1996; 78: 789-93
147. 147. Buzdar AU, Smith R, Vogel C, et al. Fadrozole HCI (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma. Cancer 1996; 77: 2503-13
148. 148. Sepracor Inc. Treating estrogen-dependent dieseases with (-)-fadrozole. World patent, WO 952816-A; 1995
149. 149. Vanden Bossche H, Willemsens U, Roels I, et al. R76713 and enantiomers: selective nonsteroidal inhibitors of the cytochrome P450-dependent oestrogen synthesis. Biochem Pharmacol 1990; 40: 1707-18
150. 150. Wouters W, De Coster R, van Dun J, et al. Comparative effects of the aromatase inhibitor R76713 and of its enantiomers R83839 and R83842 on steroid biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol 1990; 37 (6): 1049-54
151. 151. De Coster, van Ginkal RF, Callens MJL, et al. Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors. Cancer Res 1992; 52: 1240-4
152. 152. Wouters W, De Coster R, Beerens D, et al. Pharmacology of vorozole. J Steroid Biochem Mol Biol 1993; 44: 617-21
153. 153. Wouters W, De Coster R, Frekels M, et al. R76713, a new specific non-steroidal aromatase inhibitor. J Steroid Biochem 1989; 34: 781-8
154. 154. Wouters W, De Coster R, Tuman RW, et al. Aromatase inhibition by R76713: experimental and clinical pharmacology. J Steroid Biochem 1989; 34: 427-30
155. 155. Van der Wall E, Donker TH, der Frankrijker E, et al. Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in health postmenopausal women. Cancer Res 1993; 53: 4563-6
156. 156. De Coster R, Wouters W, Bowden CR, et al. New non-steroidal aromatase inhibitors: focus on R76731. J Steroid Biochem Mol Biol 1990; 37 (3): 335-41
157. 157. Dowsett M, Johnston SRD, Doody D, et al. The clinical and endocrine effects of the oral aromatase inhibitor vorozole in human breast cancer [abstract 85]. Proc Am Soc Clin Oncol 1994; 13: 71
158. 158. Goss PE, Clark RM, Ambus U, et al. Phase II study of vorozole (R83842), a new aromatase inhibitor in postmenopausal women with advanced breast cancer in progression from tamoxifen. Clin Cancer Res 1995; 1: 287-94
159. 159. Boccardo F, Amoroso D, Iacobelli S, et al. Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study. Ann Oncol 1997; 8: 745-50
160. 160. Paridaens R, Roy JA, Nooij M, et al. Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational drug branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast cancer cooperative group. Anticancer Drugs 1998; 9: 29-35
161. 161. Goss P, Wine E, Tannock I, et al. Vorozole versus Megace7 in postmenopausal patients with metastatic breast carcinoma who had relapsed following tamoxifen [abstract no. 542]. Proc Am Soc Clin Oncol 1997; 16: 155a
162. 162. Bergh J, Bonneterre J, Illiger HJ, et al. Vorozole (Rivizor) versus aminoglulethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen [abstract no. 543]. Proc Am Soc Clin Oncol 1997; 16: 155a
163. 163. Wiseman LR, Spencer CM. Vorozole. Drugs Aging 1997; 11: 245-50
164. 164. Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 1994; 30: 103-11
165. 165. Plourde PV, Dyroff M, Dowset, M, et al. Arimidex: a new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 1995; 53: 175-9
166. 166. Yates KA, Dowsett M, Fisher GV, et al. Arimidex (ZD 1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 1996; 73: 543-8
167. 167. Zeneca Pharma, Arimidex, product monograph 95/5139. 1995 Sep. section 6
168. 168. Buzdar A, Jonat W, Howell A, et al. Anastrozole (ARIMIDEX), a potent and selective aromatase inhibitor versus megesterol acetate (MEGACE) in postmenopausal women with advanced breast cancer: results of an overview analysis of two phase III trials. J Clin Oncol 1996; 14: 2000-11
169. 169. Jonat W, Howell A, Blomqvist C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole ('ARIMIDEX') with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996; 32A: 404-12
170. 170. Crutz JM, Muss HB, Brockschmidt JK, et al. Weight changes in women with metastic breast cancer treated with megesterol acetate: a comparison of standard versus high-dose therapy. Semin Oncol 1990; 17: 63-7
171. 171. Buzdar A, Jonat W, Howell A, Arimidex International Study Group, et al. Significant improved survival with Arimidex (anastrozole) versus megestrol acetate in postmenopausal advanced breast cancer: updated results of two randomized trials [abstract no. 545]. Proc Am Soc Clin Oncol 1997; 16: 156a
172. 172. Buzadar A, Jonat W, Howell A, et al. Arimidex: a potent and selective inhibitor for the treatment of advanced breast cancer. J Steroid Biochem Mol Biol 1997; 61: 145-9
173. 173. Wiseman LR, Adkins JC. Anastrozole: a review of its use in the management of postmenopausal women with advanced breast cancer. Drugs Aging 1998; 13: 321-32
174. 174. Bhatnagar AS, Hausler A, Trunet P, et al. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 1990; 37: 1021-7
175. 175. Bhatnagar AS, Hausler A, Schieweck K. Inhibition of aromatase in vitro and in viro by aromatase inhibitors. J Enzyme Inhib 1990; 4: 179-86
176. 176. Trunet PF, Mueller Ph, Bhatnagar AS, et al. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor CGS 20267, in healthy male subjects. J Clin Endocrinol Metab 1993; 77: 319-23
177. 177. Iverson TJ, Smith IE, Ahern J, et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab 1993; 77: 324-31
178. 178. Iverson TJ, Smith IE, Ahern J, et al. Phase I study of the oral non-steroidal aromatase inhibitor CGS 20267 in postmenopausal patients with breast cancer. Cancer Res 1993; 53: 266-70
179. 179. Lipton A, Demers LM, Harvey HA, et al. Letrozole (CGS 20267): a phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 1995; 75: 2132-8
180. 180. Bisagni C, Cocconi G, Seaglione F, et al. Letrozole, a new oral nonsteroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer: a pilot study. Ann Oncol 1996; 7: 99-102
181. 181. Tominaga T, Ohashi Y, Abe R, et al. Phase II trial of letrozole (a novel oral nonsteroidal aromatase inhibitor) in postmenopausal patients with advanced or recurrent breast cancer [abstract 373]. Eur J Cancer 1995; 31A Suppl. 5: S81
182. 182. Dombernowsky P, Smith I, Falkson G, et al. Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose-effect and superiority of 2.5mg letrozole over megestrol acetate (MA) [abstract no. 46]. Proc Am Soc Clin Oncol 1996; 15: 100
183. 183. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453-61
184. 184. Marty M, Gershanovich M, Campos B, Letrozole International Trial group (AR/BC3), et al. Letrozole, a new potent, selective aromatase inhibitor (A1) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with anti-estrogens [abstract no. 544]. Proc Am Soc Clin Oncol 1997; 16: 156a
185. 185. Carrion RP, Candel VA, Calabresi F, et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 1994; Suppl. 7: S19-S24
186. 186. Thurlimann B, Beretta K, Bacchi M, et al. First line fadrozole HCl (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Ann Oncol 1996; 7: 471-9
187. 187. Dowsett M. Future use for aromatase inhibitors in breast cancer. J Steroid Biochem Mol Biol 1998; 69: 709-13
188. 188. Harvey HA. Emerging role of aromatase inhibitors in the treatment of breast cancer. Oncology (Huntingt) 1998; 12 (3 Suppl. 5): 32-5
189. 189. Lubet RA, Steele VE, Casebolt TT, et al. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis 1994; 15: 2775-80
190. 190. Kelloff GJ, Lubet RA, Lieberman R, et al. Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1998; 7 (1): 65-78
191. 191. Takayama K, Zeitoun K, Gunby RT, et al. Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 1998; 69 (4): 709-13
192. 192. Smigel K. Breast cancer preventive trials show major benefits, some risk. J Natl Cancer Inst 1998; 90: 647-8
193. 193. Bruzzi P. Tamoxifen for the prevention of breast cancer. Important questions remain unanswered, and existing trials should continue. BMJ 1998; 316: 1181-2